Alzheimer's disease

Alector IPO Banks $176M to Test Alzheimer’s Drugs in Clinical Trials
Alector IPO Banks $176M to Test Alzheimer’s Drugs in Clinical Trials
Xconomy
Alector
IPOs
Alzheimer's disease
Flag link:
All Eyes on Biogen as Roche Alzheimer’s Drug Flunks Final Test
All Eyes on Biogen as Roche Alzheimer’s Drug Flunks Final Test
Xconomy
Roche
Alzheimer's disease
clinical trials
AC Immune
crenezumab
Biogen
aducanumab
Flag link:
Spinraza sales lift Biogen revenues
Spinraza sales lift Biogen revenues
BioCentury
Biogen
earnings
aducanumab
Alzheimer's disease
Flag link:
Wren raises £18M to drug protein-misfolding diseases
Wren raises £18M to drug protein-misfolding diseases
Fierce Biotech
Wren Therapeutics
protein-misfolding
Alzheimer's disease
Flag link:
3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
Motley Fool
FDA
gene editing
Novartis
Sarepta Therapeutics
CAR-T
Alzheimer's disease
Flag link:
Alzheon hits another dead end funding its Alzheimer's program, pulls second IPO attempt
Alzheon hits another dead end funding its Alzheimer's program, pulls second IPO attempt
Endpoints
Alzheon
IPOs
clinical trials
ALZ-801
Alzheimer's disease
Flag link:
FDA Gives Amneal's Generic Alzheimer’s & Parkinson’s Patch a Thumbs-Up
FDA Gives Amneal's Generic Alzheimer’s & Parkinson’s Patch a Thumbs-Up
BioSpace
FDA
Amneal
generics
Novartis
Exelon Patch
Alzheimer's disease
Parkinson's Disease
Flag link:
The Anti-Alzheimer's BOLD Act Isn't. But It Could Be A Step In The Right Direction
The Anti-Alzheimer's BOLD Act Isn't. But It Could Be A Step In The Right Direction
Forbes
Alzheimer's disease
BOLD Act
dementia
Flag link:
Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs
Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs
Xconomy
IPOs
Alector
Alzheimer's disease
dementia
Flag link:
Pair of deals boosts Biogen’s early-stage CNS pipeline
Pair of deals boosts Biogen’s early-stage CNS pipeline
Pharmaforum
Biogen
CNS
Alzheimer's disease
MS
C4 Therapeutics
Skyhawk Therapeutics
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug
Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug
Fierce Biotech
Eli Lilly
AC Immune
Alzheimer's disease
tau
Flag link:
Eisai, UCL to launch phase I trials of E2814 for Alzheimer’s disease
Eisai, UCL to launch phase I trials of E2814 for Alzheimer’s disease
Pharmaceutical Business Review
Eisai
Alzheimer's disease
E2814
clinical trials
University College London
Flag link:
Finding of dementia genes could speed drug discovery in Alzheimer’s and other brain disorders
Finding of dementia genes could speed drug discovery in Alzheimer’s and other brain disorders
Fierce Biotech
UCLA
Alzheimer's disease
dementia
drug discovery
Flag link:
Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019
Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019
CP Wire
biotech
Alzheimer's disease
NASH
RNA
gene therapy
immuno-oncology
orphan diseases
Flag link:
Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019
Alzheimer's disease
NASH
RNA
gene therapy
immuno-oncology
orphan diseases
Flag link:
UT Researchers Discover Alzheimer's Vaccine, Hope To Test In Humans Soon
UT Researchers Discover Alzheimer's Vaccine, Hope To Test In Humans Soon
Forbes
Alzheimer's disease
R&D
vaccines
University of Texas
Flag link:
AbbVie enlists protein degradation experts at Mission for a new bet on Alzheimer's, Parkinson's
AbbVie enlists protein degradation experts at Mission for a new bet on Alzheimer's, Parkinson's
Endpoints
targeted protein degradation
AbbVie
Mission Therapeutics
Alzheimer's disease
Parkinson's Disease
Flag link:
Eli Lilly backs away from Bace but not from novel Alzheimer’s targets
Eli Lilly backs away from Bace but not from novel Alzheimer’s targets
EP Vantage
Eli Lilly
drug development
Alzheimer's disease
BACE inhibitors
Flag link:

Pages